The Companion Diagnostics (CDX) Market Forecast 2016-2026
LONDON, April 15, 2016 /PRNewswire/ --
Leading Companies, Trends and Developments in the Growing Theranostics Market
What can be expected from the Companion Diagnostics market? Which areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects there.
Our 192-page report provides 127 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across the whole companion diagnostics market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.
Forecasts from 2016-2026 and other analyses show you commercial prospects Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter's Five Forces analysis) and commercial developments.
The report also includes will find revenue forecasts to 2026 for the following submarkets in the companion diagnostics market: Theranostics Other Companion Diagnostics
Additionally, this report includes a forecast to 2026 for the global in vitro diagnostics market.
The report also includes will find revenue forecasts to 2026 for the following national and regional markets for companion diagnostics: US Germany France Italy Spain UK Japan China India Russia Brazil South Korea
The report provides detailed profiles of key companies operating within the companion diagnostics market: F. Hoffmann-La Roche Ltd Qiagen N.V. Abbott Laboratories Agilent Technologies Myriad Genetics bioMerieux Thermo Fisher Scientific
Leading companies and potential for market growth Overall revenue for the Companion Diagnostics market will reach $10.5bn in 2020, our work forecasts. We predict strong revenue growth through to 2026. Advances in cellular and tissue research, an improving regulatory landscape, strong support from governments in multiple regions and the launch of several new therapies in areas of unmet clinical need will drive sales to 2026.
Our work analyses the key companies in the market. See visiongain's analysis of 7 leading companies, including these: F. Hoffmann-La Roche Ltd Qiagen N.V. Abbott Laboratories Agilent Technologies Myriad Genetics bioMerieux Thermo Fisher Scientific
A company profile gives you the following information where available: Discussion of a company's activities and outlook Historic revenue, analysis and discussion of company performance over the past 5 years Analysis of major products currently on the market Acquisitions and strategic partnerships
Discover capabilities, progress, and commercial prospects, helping you stay ahead.
What issues will affect the companion diagnostics industry? Our new report discusses issues and events affecting the companion diagnostics market. You will find discussions, including qualitative analyses: Highly diverse market needing strong knowledge of key therapeutic indications Changing regulatory landscape challenging new entrants and major market players alike Emerging therapies with the potential to reshape the market
You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.
How the Companion Diagnostics: Market Forecast 2016-2026 report helps you In summary, our 192-page report gives you the following knowledge: Revenue forecasts to 2026 for the Companion Diagnostics market - discover the industry's prospects, finding promising places for investments and revenues Revenue forecasts to 2026 for each major submarket - discover prospects for leading companion diagnostics products in the following areas: theranostics and other companion diagnostics. Revenue forecasts to 2026 for twelve leading national markets - US, Germany, France, Italy, Spain, UK, Japan, China, India, Russia, Brazil and South Korea Assessment of 7 leading companies - analysis of products, revenue, mergers & acquisitions, sales by region and products Discussion of what stimulates and restrains companies and the market Prospects for established firms and those seeking to enter the market
You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain's study is for everybody needing commercial analyses for the companion diagnostics market and leading companies. You will find data, trends and predictions. Please order our report now.
Companies Mentioned in the Report 20/20 Gene Systems Abbott Laboratories Abbott Molecular AbbVie Advanced Scientifics Affymetrix Agilent Technologies Alere Alfa Aesar Almac Ambry Genetics Amgen Arca Biopharma Argene Ariosa Diagnostics Arno Astellas Pharma AstraZeneca Astute Medical Asuragen AviaraDx Bayer Bina Technologies, Biocartis Biofire Diagnostics bioMerieux Biomonitor Boehringer Ingleheim Bristol Myers-Squi CAPP Medical Caprion Proteomics Caris Life Sciences Celera (Quest Diagnostics) Celgene Cepheid Clarient Clinical Regerence Laboratory Clovis Oncology CompanDx Crescendo Bioscience Curidium Medica Dako (Agilent Technologies) DiagnoCUr Dutalys Dx Assays Eli Lilly Endocyte Epizyme Exosome Diagnostics F. Hoffmann-La Roche Ltd. Ferring Pharmaceuticals Flagship Biosciences FlowMetric Diagnostics Foundation Medicine GE Genentech GENEWEAVE Biosciences, Inc. Genfit Genia Technologies, Inc. Genmab Genmark Diagnostics Gilead Sciences GlaxoSmithKline Hexie Health HistologiX Idera Pharmaceutical IGEN International Ilumina ImmunoGen Incyte InDex Pharmaceuticals Institut Merieux Inverness Medical Innovations Invivoscribe Technologies Ipsen Ipsogen IQuum, Inc. Johnson Matthey Plc Kapa Biosystems Keysight Technologies Kimball Genetics Kunlun Health Insurance Lab 21 Lab Corp. Leica Biosystems Leica Microsystems Life Technologies Luminex MedImmune Merck & Co. Merck KGaA Merck Serono Molecular MD Myriad Genetics Nanosphere Nanostring NIH Novartis Origin Technologies Corp. OSI Pharmaceuticals Oxford BioTherapeutics Pfizer PICC Health Insurance Ping An Insurance Group PrimeraDx Prionics Progenika Biopharma Prometheus Protagen Qiagen N.V. Quest Diagnostics Quintiles Transnational Corporation Randox Pharma Services RAS Lifesciences Pvt. Ltd RiboMed Biotechnologies Saladax Biomedical Santaris Pharma A/S Seragon Pharmaceuticals Siemens Healthcare Signature Diagnostics AG Sirius Genomics Synthon Biopharmaceuticals Sysmex Inostics Takeda Pharmaceuticals Target Discovery TcLand Expression TESARO Theranostics Thermo Fisher Scientific Third Wave Technologies TIB MOLBiol Tragara Pharmaceuticals Transgenomic TrimGEn Crorporation Trophos Unilabs Ventana Medical Systems (Roche) Weisenthal Cancer Group
To see a report overview please email Sara Peerun on email@example.com
To request an exec summary of this report please email Sara Peerun at firstname.lastname@example.org or call Tel: +44(0)20-7336-6100
Or click on https://www.visiongain.com/Report/1614/The-Companion-Diagnostics-%28CDx%29-Market-Forecast-2016-2026